GlassScriptPhysician profile
Correal J Garrison
NPI 1427421528
$10,215.36
in general payments reported to CMS, 2019-2025
48 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,150 · 2022: $2,471 · 2023: $2,203 · 2024: $1,730 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,594.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,459.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $936.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $705.96 | 2021-2025 | |
| Novo Nordisk INC | $699.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $629.93 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $602.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $476.37 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.41 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.30 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $331.95 | 2021-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $324.96 | 2022 | |
| Amgen INC. | $295.37 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.65 | 2021-2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $249.29 | 2021-2022 | |
| Sk Life Science, INC. | $210.37 | 2023 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $200.07 | 2021-2024 | Trintellix |
| Abbott Laboratories | $182.48 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $178.09 | 2021-2023 | Spravato |
| Merck Sharp & Dohme LLC | $169.12 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Esperion Therapeutics, INC. | $128.70 | 2021-2025 | Nexletol |
| Lundbeck LLC | $123.78 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $115.31 | 2021 | |
| Dexcom, INC. | $106.73 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $102.26 | 2021-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $95.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $90.58 | 2021-2025 | Qelbree, Qelbree |
| Ardelyx, INC. | $80.51 | 2024-2025 | Ibsrela |
| Biogen, INC. | $73.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $70.31 | 2021-2024 | |
| Mylan Specialty L.P. | $59.14 | 2022-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $54.44 | 2024-2025 | Voquezna |
| Eisai INC. | $46.59 | 2021 | |
| Boston Scientific Corporation | $45.51 | 2024-2025 | Watchman Flx, Watchman Access System |
| Corium, LLC | $40.74 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $40.22 | 2022-2025 | |
| Shield Therapeutics INC | $36.95 | 2024-2025 | |
| Axsome Therapeutics, INC. | $32.62 | 2025 | Auvelity |
| Bausch Health US, LLC | $31.54 | 2022-2023 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $27.06 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.46 | 2025 | Recorlev |
| Sumitomo Pharma America, INC. | $20.66 | 2024 | Gemtesa |
| Collegium Pharmaceutical, INC. | $17.53 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $16.34 | 2023 | Eliquis |
| Tris Pharma INC | $15.07 | 2024 | Dyanavel Xr |
| Ucb, INC. | $13.77 | 2021 | |
| Currax Pharmaceuticals LLC | $13.23 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.67 | 2021 | |
| Daiichi Sankyo INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Correal Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.